News articles about Phibro Animal Health (NASDAQ:PAHC) have trended somewhat positive on Thursday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Phibro Animal Health earned a news impact score of 0.18 on Accern’s scale. Accern also gave press coverage about the company an impact score of 47.8560189828373 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news stories that may have impacted Accern Sentiment’s scoring:

Several equities research analysts have recently issued reports on PAHC shares. Zacks Investment Research upgraded Phibro Animal Health from a “hold” rating to a “buy” rating and set a $41.00 price target for the company in a report on Tuesday, October 31st. ValuEngine lowered Phibro Animal Health from a “buy” rating to a “hold” rating in a report on Thursday, November 9th. Piper Jaffray Companies reiterated a “buy” rating and set a $42.00 price target on shares of Phibro Animal Health in a report on Friday, November 10th. Finally, BidaskClub lowered Phibro Animal Health from a “hold” rating to a “sell” rating in a report on Saturday, December 2nd. Three analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $38.20.

Shares of Phibro Animal Health (NASDAQ PAHC) opened at $35.65 on Thursday. Phibro Animal Health has a 1-year low of $26.70 and a 1-year high of $40.25. The company has a quick ratio of 1.75, a current ratio of 3.12 and a debt-to-equity ratio of 1.82. The firm has a market capitalization of $1,424.77, a P/E ratio of 23.30, a P/E/G ratio of 2.52 and a beta of 1.18.

Phibro Animal Health (NASDAQ:PAHC) last posted its earnings results on Monday, February 5th. The company reported $0.44 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.38 by $0.06. Phibro Animal Health had a return on equity of 16.70% and a net margin of 3.42%. The firm had revenue of $205.90 million during the quarter, compared to analyst estimates of $194.90 million. During the same period in the previous year, the company earned $0.39 EPS. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. analysts predict that Phibro Animal Health will post 1.69 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 28th. Investors of record on Wednesday, March 7th will be issued a $0.10 dividend. The ex-dividend date of this dividend is Tuesday, March 6th. This represents a $0.40 annualized dividend and a yield of 1.12%. Phibro Animal Health’s dividend payout ratio (DPR) is currently 26.14%.

In related news, insider Dean J. Warras sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $35.62, for a total value of $356,200.00. Following the completion of the sale, the insider now directly owns 10,000 shares in the company, valued at approximately $356,200. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Larry Lee Miller sold 14,182 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $35.49, for a total value of $503,319.18. Following the completion of the sale, the chief operating officer now owns 8,582 shares of the company’s stock, valued at $304,575.18. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 78,754 shares of company stock valued at $2,789,185. Corporate insiders own 51.88% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Phibro Animal Health (PAHC) Stock Price” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2018/02/15/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-phibro-animal-health-pahc-stock-price.html.

About Phibro Animal Health

Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products.

Insider Buying and Selling by Quarter for Phibro Animal Health (NASDAQ:PAHC)

Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.